Abraxane is albumin-bound paclitaxel, a taxane microtubule inhibitor used in breast, lung, and pancreatic cancers in specific combination or post-treatment settings.
The FDA approved Novocure’s Optune Pax, a wearable tumor-treating fields device, for pancreatic cancer in combination with chemotherapy. Phase III PANOVA-3 data showed delayed pain progression and improved one-year overall survival in inoperable locally advanced disease.
Bristol Myers Squibb said 2025 revenue was flat as a 17% increase in growth-portfolio sales offset a 15% decline in legacy drugs. The company expects legacy sales to fall another 12-16% in 2026, with newer products such as Opdivo, Reblozyl and Breyanzi supporting results.
Healthcare sector surged 10% since Q4 2025, outpacing all S&P 500 sectors as investors rotate from tech to pharmaceutical value plays. Major drugmakers demonstrate resilience following Medicare price negotiations implementation.
Bristol Myers Squibb's growth portfolio increased 17% in 2025, partially offsetting a 15% decline in legacy products facing generic competition. The company's stock gained 11.4% in the past month on strong fourth-quarter results.
The global pancreatic cancer precision medicine market is projected to grow from US$ 610 million in 2024 to US$ 2,467.83 million by 2033 at a 16.8% CAGR, driven by advances in targeted therapies, genomic diagnostics, and liquid biopsies.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07394387 |
Neoadjuvant Study of HIFU With or Without PD-1 Inhibitors Followed by Abraxane Plus Carboplatin in Triple-Negative Breast Cancer. |
RECRUITING | PHASE2 |
| NCT07284836 |
Phase II Trial of Albumin-Bound Paclitaxel Combined With Nedaplatin (TP) Via Hepatic Arterial Infusion for Advanced Breast Cancer Patients With Liver Metastases After Failure of Standard Therapy |
RECRUITING | PHASE2 |
| NCT06745882 |
Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC |
RECRUITING | PHASE2 |
| NCT05911308 |
Abequolixron (RGX-104) and Durvalumab in Lung Cancer |
TERMINATED | PHASE1 |
| NCT05828381 |
Envafolimab Combined With Abraxane and Cisplatinas as Neoadjuvant Treatment for Resectable Esophageal Cancer |
NOT_YET_RECRUITING | PHASE2 |
| NCT05631899 |
CAR-DC Vaccine and ICIs in Local Advanced/Metastatic Solid Tumors |
ACTIVE_NOT_RECRUITING | PHASE1 |
| NCT05631886 |
Combination of CAR-DC Vaccine and ICIs in Malignant Tumors |
RECRUITING | PHASE1 |
| NCT05482893 |
Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study) |
RECRUITING | PHASE1/PHASE2 |
| NCT05239182 |
9-ING-41 Plus Retifanlimab and Gemcitabine/Nab-Paclitaxel in Patients With Advanced Pancreatic Adenocarcinoma |
TERMINATED | PHASE2 |
| NCT04639271 |
Pyrotinib, Trastuzumab And Abraxane in HER2-positive MBC With Brain Metastasis |
UNKNOWN | PHASE2 |
